The opportunity
Colossal Biosciences uses CRISPR to edit living species toward extinct relatives and ships genomic tools for conservation. Mammoth traits, dire wolves, and woolly mice are the public program; dire-wolf-trait pups are already a milestone. The business is IP, partnerships, and long-horizon species work, not a one-off lab stunt. De-extinction is a category almost nobody else can claim with living animals on camera. Conservation buyers and partners pay for the tools. The equity story is owning that genomic stack while the category is still private.
Proof of ownership publishedFrom $20Peer-to-peer bids and offers
Valuations explained
WLTH entry
$9.20B
The valuation of the private round where WLTH secured this allocation. New Slices issued from this raise are priced from this entry.
In-app
The lowest implied valuation from live Slice listings on the WLTH marketplace. It moves with what holders are asking, not with a new company round.
Company valuation
$10B
The company’s latest reported valuation (last private round, or live market cap after IPO). This is the headline number, not what you pay on WLTH.
Private-market investment. Capital is at risk and values can fall as well as rise. This is not investment advice.
Deal terms
8% below company valuation
Allocation filled
—
— left— total
WLTH entry
$9.20B
Company valuation
$10B
Structure
Slice
Liquidity
Marketplace
WLTH growth
$ 9.20B → $ 10B
+9%
1:1
Each Slice is backed 1:1 by underlying equity in this company.
Colossal Biosciences pre-IPO deal overview
Get in before the IPO. Back the de-extinction lab using CRISPR on mammoth traits, dire wolves, and conservation tools.
Paused
The opportunity
Colossal Biosciences uses CRISPR to edit living species toward extinct relatives and ships genomic tools for conservation. Mammoth traits, dire wolves, and woolly mice are the public program; dire-wolf-trait pups are already a milestone. The business is IP, partnerships, and long-horizon species work, not a one-off lab stunt. De-extinction is a category almost nobody else can claim with living animals on camera. Conservation buyers and partners pay for the tools. The equity story is owning that genomic stack while the category is still private.
Proof of ownership publishedFrom $20Peer-to-peer bids and offers
Valuations explained
WLTH entry
$9.20B
The valuation of the private round where WLTH secured this allocation. New Slices issued from this raise are priced from this entry.
In-app
The lowest implied valuation from live Slice listings on the WLTH marketplace. It moves with what holders are asking, not with a new company round.
Company valuation
$10B
The company’s latest reported valuation (last private round, or live market cap after IPO). This is the headline number, not what you pay on WLTH.
Private-market investment. Capital is at risk and values can fall as well as rise. This is not investment advice.
Deal terms
8% below company valuation
Allocation filled
—
— left— total
WLTH entry
$9.20B
Company valuation
$10B
Structure
Slice
Liquidity
Marketplace
WLTH growth
$ 9.20B → $ 10B
+9%
1:1
Each Slice is backed 1:1 by underlying equity in this company.
Colossal Biosciences in the news
Latest coverage and WLTH writing about this company.
News
What you’re actually buying
Pre-IPO means investing before a company lists publicly, when access is usually locked to insiders. Here's how WLTH opens it up.
A private round
Colossal Biosciences raised capital at a ~$10B company valuation, long before any IPO.
WLTH gets an allocation
WLTH secures a slice of that round, normally reserved for large institutions.
You own a Slice
You get tokenized economic exposure to the underlying asset backed 1:1 and verifiable. Self custodied and tradable at any time.
No paperwork, no five-figure minimums. Own a Slice from $20, with payouts in USDC.
Frequently asked questions
What is a WLTH Slice?
A tokenized position backed 1:1 by real underlying equity in the company, not a synthetic price tracker.
What's the minimum?
You can invest from $20. Available to eligible users outside the US and UK.
Can I sell before an IPO?
You may be able to list your Slice on the WLTH marketplace, subject to terms and demand. Liquidity is not guaranteed.
How is my Slice backed?
Your Slice is a contractual economic right tied to a WLTH allocation. Review the fund offering documents for structure and risks.
What is Colossal Biosciences on WLTH?
Colossal Biosciences on WLTH is fractional, tokenized pre-IPO exposure backed by equity in the underlying private company. Investors buy slices from published valuations, track diligence in the app, and may trade on the WLTH Marketplace after listing. Minimums and availability depend on the live fund.
Paused
Invest in Colossal Biosciences pre-IPO on WLTH
Get in before the IPO. Back the de-extinction lab using CRISPR on mammoth traits, dire wolves, and conservation tools.
WLTH entry
$9.20B
Company valuation
$10B
Colossal Biosciences investors include
The opportunity
Colossal Biosciences uses CRISPR to edit living species toward extinct relatives and ships genomic tools for conservation. Mammoth traits, dire wolves, and woolly mice are the public program; dire-wolf-trait pups are already a milestone. The business is IP, partnerships, and long-horizon species work, not a one-off lab stunt. De-extinction is a category almost nobody else can claim with living animals on camera. Conservation buyers and partners pay for the tools. The equity story is owning that genomic stack while the category is still private.
Proof of ownership publishedFrom $20Peer-to-peer bids and offers
Valuations explained
WLTH entry
$9.20B
The valuation of the private round where WLTH secured this allocation. New Slices issued from this raise are priced from this entry.
In-app
The lowest implied valuation from live Slice listings on the WLTH marketplace. It moves with what holders are asking, not with a new company round.
Company valuation
$10B
The company’s latest reported valuation (last private round, or live market cap after IPO). This is the headline number, not what you pay on WLTH.
Private-market investment. Capital is at risk and values can fall as well as rise. This is not investment advice.
Deal terms
8% below company valuation
Allocation filled
—
— left— total
WLTH entry
$9.20B
Company valuation
$10B
Structure
Slice
Liquidity
Marketplace
WLTH growth
$ 9.20B → $ 10B
+9%
1:1
Each Slice is backed 1:1 by underlying equity in this company.
Colossal Biosciences in the news
Latest coverage and WLTH writing about this company.
News
What you’re actually buying
Pre-IPO means investing before a company lists publicly, when access is usually locked to insiders. Here's how WLTH opens it up.
A private round
Colossal Biosciences raised capital at a ~$10B company valuation, long before any IPO.
WLTH gets an allocation
WLTH secures a slice of that round, normally reserved for large institutions.
You own a Slice
You get tokenized economic exposure to the underlying asset backed 1:1 and verifiable. Self custodied and tradable at any time.
No paperwork, no five-figure minimums. Own a Slice from $20, with payouts in USDC.
Frequently asked questions
What is a WLTH Slice?
A tokenized position backed 1:1 by real underlying equity in the company, not a synthetic price tracker.
What's the minimum?
You can invest from $20. Available to eligible users outside the US and UK.
Can I sell before an IPO?
You may be able to list your Slice on the WLTH marketplace, subject to terms and demand. Liquidity is not guaranteed.
How is my Slice backed?
Your Slice is a contractual economic right tied to a WLTH allocation. Review the fund offering documents for structure and risks.
What is Colossal Biosciences on WLTH?
Colossal Biosciences on WLTH is fractional, tokenized pre-IPO exposure backed by equity in the underlying private company. Investors buy slices from published valuations, track diligence in the app, and may trade on the WLTH Marketplace after listing. Minimums and availability depend on the live fund.